Snakebit Angion reports another miss for lead program, as biotech prepares to shift its 'primary focus'
Angion’s lead organ damage drug took two strikes earlier this year, flopping as a repurposed effort for Covid-19 and whiffing in high-risk kidney transplant patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
